Immune cell therapy shows promise in early trial for advanced cancers
NCT ID NCT04050709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new immune cell therapy called PD-L1 t-haNK in 16 adults with advanced solid cancers that had spread or could not be removed by surgery. The main goals were to check safety, find the best dose, and see if the treatment could shrink tumors. The therapy uses specially designed natural killer cells to target cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Tissue analysis may guide personalized cancer therapy
- Can a new tracer light up cancer growth?